Biologic immune modifiers: Trials and tribulations-are we there yet?

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 6, 2006, Pages 1209-1215

  Ballow, Mark ^a  

^a CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

allergic diseases; asthma; Biologic agents; fusion proteins; immune response modifiers; mAbs; recombinant proteins

Indexed keywords

ABATACEPT; ADALIMUMAB; ALLERGEN; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G4; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 13 ANTIBODY; KELIXIMAB; LUMILIXIMAB; MEPOLIZUMAB; METHACHOLINE; MONOCLONAL ANTIBODY; NATALIZUMAB; OMALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; SOLUBLE INTERLEUKIN 13 RECEPTOR; SOLUBLE INTERLEUKIN 4 RECEPTOR; TGN 1412; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ARTICLE; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IN VITRO STUDY; INFECTION; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; RECEPTORS, IGE; RECOMBINANT PROTEINS;

EID: 33845334892     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.09.024     Document Type: Article

References (50)

1. Busse W.W., and Lemanski Jr. R.F. Asthma. N Engl J Med 344 (2001) 350-362
2. Ballow M. -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?. J Allergy Clin Immunol 116 (2005) 738-743
3. Liossis S.-N.C., and Tsokos G.C. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 116 (2005) 721-729
4. Schulman E.S. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164 (2001) S6-S11
5. Boushey Jr. H.A. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 108 (2001) S77-S83
6. Milgrom H., Fick Jr. R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341 (1999) 1966-1973
7. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005) 309-316
8. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of amalizumab. Respir Med 100 (2006) 1907-1917
9. Poole J.A., Meng J., Reff M., Spellman M.C., and Rosenwasser L.J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 116 (2005) 780-788
10. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti I.M., et al. Interleukin-4 receptor in moderate atopic asthma. Am J Respir Crit Care Med 160 (1999) 1816-1823
11. Kon O.M., Sihra B.S., Compton C.H., Leonard T.B., Kay A.B., and Barnes N.C. Randomized, dose-ranging placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352 (1998) 1109-1113
12. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
13. Flood-Page P., Menzies-Gow A., Kay A.B., and Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003) 199-204
14. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
15. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2003) 115-119
16. Busse W.W., Baker J.W., Charous B.L., Chervinsky P., Kim K.T., Gross G.N., et al. Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma. J Allergy Clin Immunol 113 (2004) S286-S287
17. Nelson H.S., Busse W.W., Israel E., Baker J.W., Charous B.L., Kim K.T., et al. Daclizumab improves asthma control in patients with refractory asthma. [abstract]. J Allergy Clin Immunol 115 (2005) S134
18. Sornasse T.R., Hong W., Schreck R., Zhang Y., Sheridan J., Shi J., et al. Daclizumab in vitro inhibits the secretion of pro-asthmatic and pro-inflammatory cytokines by activated T-cells. [abstract]. J Allergy Clin Immunol 115 (2005) S73
19. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., et al. Interleukin-13: central mediator of allergic asthma. Science 282 (1998) 2258-2261
20. Yang G., Li L., Volk A., Emmell E., Petley T., Giles-Komar J., et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther 313 (2005) 8-15
21. Blanchard C., Mishra A., Saito-Akei H., Monk P., Anderson I., and Rothenberg M.E. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 35 (2005) 1096-1103
22. Grunig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 (1998) 2261-2263
23. Weaver A.L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43 suppl 3 (2004) iii17-iii23
24. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev 2 (2002) 364-371
25. Prete M., Perosa F., Favoino E., and Dammacco F. Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. Clin Exp Med 5 (2005) 141-160
26. Thomas P.S. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 79 (2001) 132-140
27. Thomas P.S., and Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57 (2002) 774-778
28. Broide D.H., Lotz M., Cuomo A.J., Coburn D.A., Federman E.C., and Wasserman S.I. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 89 (1992) 958-967
29. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 (2005) 1012-1018
30. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 354 (2006) 697-708
31. Erin E.M., Leaker B.R., Nicholson G.C., Tan A.J., Green L.M., Neighbour H., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α (TNF-α) in asthma. Am J Respir Crit Care Med 174 (2006) 753-762
32. Reiser H., and Stadecker M.J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335 (1996) 1369-1377
33. Moreland L., Bate G., and Kirkpatrick P. Fresh from the pipeline: abatacept. Nat Rev Drug Discov 5 (2006) 185-186
34. Genovese M.C., Becker J.-C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition. N Engl J Med 353 (2005) 1114-1123
35. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
36. Polte T., Foell J., Werner C., Hoymann H.G., Braun A., Burdach S., et al. CD137-mediated immunotherapy for allergic asthma. J Clin Invest 116 (2006) 1025-1036
37. Bochner B.S. Adhesion molecules as therapeutic targets. Immunol Allergy Clin North Am 24 (2004) 615-630
38. Bennett J.S. Novel platelet inhibitors. Annu Rev Med 52 (2001) 161-184
39. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
40. Gauvreau G.M., Becker A.B., Boulet L.P., Chakir J., Fick R.B., Greene W.L., et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 112 (2003) 331-338
41. von Andrian U.H., and Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348 (2003) 68-72
42. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P.A., Libonati M.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 (2003) 15-23
43. Corren J., Casale T., Lanier B.Q., Blogg M., Reisner C., and Gupta N. Omalizumab is well tolerated in adolescent/adult patients (>12 years) with moderate-severe asthma. [abstract]. J Allergy Clin Immunol 115 (2005) S75
44. Fernandez C., Busse W., Reisner C., and Gupta N. Clinical data do not suggest a causal relationship between omalizumab therapy and cancer. [abstract]. Proc Am Thorac Soc 2 (2005) A359
45. Kong J.S.W., Teuber S.S., and Gershwin M.E. Potential adverse events with biologic response modifiers. Autoimmun Rev 5 (2006) 471-485
46. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
47. Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 suppl 3 (2005) S194-S198
48. Lee S.J., and Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol 116 (2005) 900-905
49. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006) 1018-1028
50. O'Byrne P.M. Cytokines or their antagonists for the treatment of asthma. Chest 130 (2006) 244-250